Weiyuan Medicine: Fully Automated Metagenomic NGS Laboratory Solution for Pathogen Detection — Featured in Artery Select New Product Showcase Episode 63

With the continuous advancement of sequencing technologies and growing demands for clinical applications,Metagenomic Next-Generation Sequencing (mNGS) for Pathogen DetectionGradually transitioning from the laboratory to clinical practice, this technology is garnering increasing attention and adoption among healthcare institutions. On one hand, there is an urgent clinical need for rapid and accurate diagnosis of infectious diseases; on the other hand, with the deepening of healthcare reform and the advancement of medical standards, healthcare institutions are imposing increasingly stringent requirements on pathogen detection. In order toEnhancing the Timeliness of Infection Detection and the Accuracy of Pathogen Identification, Strengthening Integrated Surveillance and Long-Term Development of Hospital-Acquired Infection Pathogens, Establishing a Local Laboratory for Pathogen Metagenomic Testingbecomes critically important.

Metagenomic Sequencing Technology(Metagenomic Next-Generation Sequencing, mNGS) identifies nucleic acid sequences of pathogenic microorganisms by sequencing all nucleic acids in a sample and analyzing the data, thereby diagnosing the etiologic agents of infectious diseases. This technology offers advantages such as being unbiased, comprehensive, and highly efficient; it does not require culture and can simultaneously detect various pathogens, including bacteria, fungi, viruses, and parasites.The sole precision diagnostic and personalized medicine technology in the field of infectious disease diagnosis. The overall technical workflow of mNGS can be divided into two parts: wet lab and dry lab.

Since its establishment, WILLINGMED has focused on the field of precision diagnosis for infectious diseases, continuously launching new technologies and products. To address localized testing needs, WILLINGMED has introduced"End-to-End Automated Solution for Pathogen Metagenomics", to establish a truly localized, one-stop, high-performance automated workflow for pathogen metagenomic testing, drive innovation and development in molecular diagnostics for infectious diseases, and provide scientific, precise, and effective support for disease prevention, diagnosis, and treatment.

On Thursday, May 23, at 19:30, the 63rd session of VCBeat Select New Product Review invitesDr. Gai Wei, CEO of WILLINGMED、WILLINGMED Senior Product Manager, Liu Xujia, bringing“Fully Automated Solution for Pathogen Metagenomics Laboratory”product promotion.

Fully Automated Solution for Pathogen Metagenomics Laboratory:

From "Testing" to "Reporting": One-Stop High-Performance Automated Detection

Automation

Intelligentization

Flexibility

Standardization

Scan the QR code on the poster to add our assistant and reserve your spot for the live broadcast.

Dr. Gai Wei

CEO of WILLINGMED

Ph.D., Senior Engineer

Beijing Science and Technology Rising Star

Beijing Excellent Young Key Talent

Outstanding Young Engineer of Beijing

Former Deputy Director of the Institute of Translational Medicine, CapitalBio Corporation

Expert, Beijing Economic-Technological Development Area Expert Think Tank

Member of the Third Youth Federation of Beijing Economic-Technological Development Area

Committee Member, Clinical Microbiology and Infection Branch of the China International Exchange and Promotive Association for Medical and Health Care

2022 China Association for Science and Technology “Innovation China” Pioneer in Entrepreneurship and Employment

With over a decade of deep expertise in the field of precision detection of pathogenic microorganisms, I have served as a core member in the research and development of multiple national major projects. I have long been dedicated to developing clinical infectious disease diagnostic products based on high-throughput sequencing and microfluidic chip platforms. I have published more than ten articles in journals such as Nucleic Acids Res., Emerg. Infect. Dis., and Clin. Infect. Dis., filed over 30 patent applications, and obtained 17 software copyrights.

Liu Xujia

Senior Product Manager at WILLINGMED

Huazhong Agricultural University, Master of Molecular Biology

Over 5 years of experience in the application and promotion of NGS technology

Possesses in-depth insights into the localization and clinical application of pathogenic microbial metagenomics.

Extensive experience in NGS multi-omics and cross-disciplinary applications

WILLINGMED was established in September 2019. Focusing on the field of precision medicine for infections, it specializes in the research and development, production, and sales of gene sequencing products. Leveraging its mNGS sequencing technology platform, the company provides users with comprehensive technical services and innovative solutions.

Having specialized in precision molecular diagnostics for infectious diseases for over a decade, the company has launched the “Fully Automated Solution for Metagenomic Next-Generation Sequencing (mNGS) Laboratories” to address localized application scenarios. This solution comprises the PathoLab® Automated Pathogen Laboratory System and the PathoReport® Automated Intelligent Reporting System.

Establish a high-performance, automated, one-stop metagenomic next-generation sequencing (mNGS) workflow for pathogen detection that is truly adaptable to local implementation, drive innovation and development in molecular diagnostics for infectious diseases, and provide scientific, precise, and effective support for disease prevention, diagnosis, and treatment.

“Artery Select New Product Launch” is a live-streaming program under the “Artery Select” brand, dedicated to supporting medical enterprises in launching innovative products. The program’s mission is: to empower every milestone launch of innovative medical products.

Scan the QR code below to contact the assistant and schedule a live stream.

(If already added, please proactively ask the assistant)